secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2026-07-06T20:15:17+00:00
Accession:  0001193125-26-296200
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight lowers FY2026 sales guidance, reports Q2 prelim revenue $32-34M, Alcon collaboration
--------------------------------------------------------------------------------

- Preliminary Q2 2026 revenue $32-34M, including $5-7M from Alcon collaboration; sales ~$27M (24,917 LAL units, 11 LDD units).
- FY2026 sales guidance lowered to $110-120M (from $120-135M); total revenue guidance $140-160M including collaboration revenue $30-40M.
- Gross margin guidance raised to 73-75% (from 70-72%); operating expense guidance unchanged at $150-160M.
- Strategic collaboration with Alcon to develop light-adjustable presbyopia-correcting IOLs; pipeline includes next-gen LAL, LAL+, LAL Toric.
- Cash and investments ~$209M as of June 30, 2026; cites competitive trialing as headwind.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526296200/0001193125-26-296200-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526296200/rxst-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-296200

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer